HC Wainwright Reiterates Buy Rating for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They presently have a $50.00 price objective on the biotechnology company’s stock. HC Wainwright also issued estimates for Actinium Pharmaceuticals’ FY2026 earnings at $4.10 EPS, FY2027 earnings at $7.94 EPS and FY2028 earnings at $10.75 EPS.

Other analysts also recently issued research reports about the company. Maxim Group raised their price target on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, March 19th. StockNews.com cut Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, March 19th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $21.00 target price on shares of Actinium Pharmaceuticals in a research report on Monday, April 1st. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Actinium Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $25.72.

Actinium Pharmaceuticals Stock Performance

NYSEAMERICAN:ATNM opened at $7.69 on Monday. Actinium Pharmaceuticals has a 52 week low of $4.00 and a 52 week high of $9.86. The company has a market cap of $226.09 million, a price-to-earnings ratio of -4.20 and a beta of 0.01.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last released its earnings results on Friday, March 29th. The biotechnology company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.21. The firm had revenue of $0.08 million for the quarter. On average, research analysts forecast that Actinium Pharmaceuticals will post -1.87 earnings per share for the current fiscal year.

Institutional Trading of Actinium Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Brandywine Global Investment Management LLC acquired a new stake in shares of Actinium Pharmaceuticals in the third quarter worth $1,033,000. Creative Financial Designs Inc. ADV boosted its position in Actinium Pharmaceuticals by 19.1% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock valued at $101,000 after purchasing an additional 3,175 shares during the last quarter. Finally, Sanders Morris Harris LLC acquired a new stake in Actinium Pharmaceuticals during the first quarter valued at $78,000. Institutional investors and hedge funds own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.